A Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK)'s Infanrix Hexa Vaccine (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis Vaccine (DTaP5-HBV-IPV-Hib) in Healthy Infants and Toddlers

Inclusion Criteria: * Subjects' parent(s)/Legally Acceptable Representative(s) (LAR\[s\]) who, in the opinion of the investigator, could and would comply with the requirements of the protocol (e.g., return for follow-up visits). * Written or witnessed/thumb printed informed consent obtained from the parent(s)/LAR(s) of the subject prior to performing any study specific procedure. * A male or female child between and including 6 and 12 weeks of age (42 to 84 days) at the time of the first vaccination. * Subject born after at least 37 weeks of gestation. * Healthy subjects as established by the investigator based on medical history and the clinical examination before entering into the study. Exclusion Criteria: * Any clinical condition that, in the opinion of the investigator, might pose any risk to the subject due to participation in the study. As with other vaccines, administration of DTPa-HBV-IPV/Hib should be postponed in subjects suffering from acute severe febrile illness. The presence of a minor infection is not a contraindication. * Known history of diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Hib diseases since birth. * History of any reaction or hypersensitivity likely to be caused or exacerbated by any excipient or active component of the vaccine(s). * Any confirmed or suspected immunosuppressive or immunodeficient condition, including malignancies, based on medical history and physical examination (no laboratory testing required). * Family histo…